TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00821366

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ARV peer adherence support (PAS)
Description: Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ARV peer adherence support (PAS)
Description: Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional support
Description: Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARV treatment
Description: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARV treatment
Description: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARV treatment
Description: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
Study: NCT05436886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurogabin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parketin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parketin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
Study: NCT02262884

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SurgiQuest AirSeal Insufflation System (AIS)
Description: Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SurgiQuest AirSeal Insufflation System (AIS)
Description: Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Insufflation System (CIS)
Description: Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
Study: NCT03687138

Intervention type: OTHER
Intervention: 24h urin sample
Description: The samples will analyzed by proteomic techniques

Intervention type: OTHER
Intervention: 24h urin sample
Description: The samples will analyzed by proteomic techniques
Study: NCT01314976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis.
Study: NCT00274768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
Study: NCT04453904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sequential radiochemotherapy in a sanwich mode
Description: Patients will randomized into two different modalities of radiochemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sequential radiochemotherapy in a sanwich mode
Description: Patients will randomized into two different modalities of radiochemotherapy.
Study: NCT00871377

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn oil (n-6 fatty acids)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Fish Oil
Description: n-3 fatty acids, 1060 mg EPA + DHA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Fish Oil
Description: n-3 fatty acids, 2160 mg EPA + DHA
Study: NCT00975429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
Study: NCT02152358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciclovir
Description: Intravenous 15 mg/kg/d during 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: intravenous 10 mg/kg/d for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04579796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound exam
Description: An abdominal ultrasound exam to assess the placenta implantation site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy diagnostic
Description: Diagnostic hysteroscopy to asses the placenta implantation site.
Study: NCT04781569

Intervention type: OTHER
Intervention: data collection
Description: Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.

Intervention type: OTHER
Intervention: data collection
Description: Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: 2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: 2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.

Intervention type: DIAGNOSTIC_TEST
Intervention: nose swabs
Description: 2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.

Intervention type: DIAGNOSTIC_TEST
Intervention: nose swabs
Description: 2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative tissue samples
Description: Intraoperative tissue samples from the site of infection during surgery will be taken in the patient.
Study: NCT01590394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large plastic biliary stent
Description: Stent placement for bile duct obstruction.
Study: NCT03050216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total
Study: NCT03796234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary and physiotherapy
Description: 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
Study: NCT01231802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
Study: NCT03796234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
Study: NCT03659760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Isolated
Description: Eyes closed with patch and ears plugged between 24:00-06:00
Study: NCT02703701

Intervention type: BEHAVIORAL
Intervention: Physician at triage
Description: A physician embedded at triage

Intervention type: OTHER
Intervention: Usual Care
Description: No physician at triage
Study: NCT01093755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexlansoprazole
Description: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Escalating doses of omeprazole (20-60 mg/day) for 6 months
Study: NCT03388996

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiomes
Description: 16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiomes
Description: 16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
Study: NCT03497260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain water
Description: Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain water
Description: Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
Study: NCT04404686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Per vagina administration of 100 mg followed by a second 100 mg dosage the following day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
Study: NCT01429350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
Description: 0.9mg/kg to a maximum of 90mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penumbra System
Description: The Penumbra System is an aspiration based mechanical thrombectomy device
Study: NCT00716859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Timolol 0.5% dosed twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost
Description: Latanoprost 0.005% ophthalmic solution dosed once-daily
Study: NCT01130727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: green tea extract
Description: 1.21g of green tea extract (965 mg of flavonols)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cocoa extract rich in polyphenols
Description: 2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low polyphenol cocoa extract
Description: placebo
Study: NCT02990117

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT03072914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC with RIPostC
Description: The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
Study: NCT02897882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung transplant
Description: Pain evaluation
Study: NCT03930121

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
Description: Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
Description: Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
Study: NCT02467608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid with HUEXC030 and RZE
Description: Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months

Intervention type: DRUG
Group type: OTHER
Intervention: HRZE
Description: the same as experimental group,without the excipient of HUEXC030 only
Study: NCT04375852

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of autoantibodies
Description: Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
Study: NCT01068379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: criopexy
Description: he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser
Description: Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
Study: NCT02566993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (PM01183)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin (DOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CTX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine (VCR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Study: NCT06709287

Intervention type: OTHER
Intervention: clear aligners
Description: The investigators measured pain and chewing performance at 8 time points during the first 6 months.

Intervention type: OTHER
Intervention: orthodontic metal bracket
Description: Conventional metal bracket.
Study: NCT04113798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 1 Assessments
Description: Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 1 Assessments
Description: Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 2 Fear Learning
Description: Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 2 Fear Learning
Description: Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 Fear Extinction
Description: Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 3 Fear Extinction
Description: Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Exercise
Description: Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for the full duration of 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Day 4 Recall of Fear Extinction
Description: During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 4 Recall of Fear Extinction
Description: During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
Study: NCT00970658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salonsip plaster
Description: The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sabia plaster
Description: The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
Study: NCT02190981

Intervention type: DEVICE
Intervention: Ultrasound for Small Bowel Obstruction
Description: Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction